Morphosys, GSK Ink $586M Pact for MOR103 in RA, MS
By Cormac Sheridan
Tuesday, June 4, 2013
GlaxoSmithKline plc is in-licensing MOR103, an antibody in clinical development in rheumatoid arthritis and multiple sclerosis at veteran antibody developer Morphosys AG, in return for an up-front payment of €22.5 million (US$29 million), plus another potential €423 million in milestones linked to its progress through clinical development, regulatory approval and sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.